Navigation Links
Cascal N.V. To Present at JPMorgan 2008 Basics & Industrials Conference
Date:5/28/2008

LONDON, May 28 /PRNewswire-FirstCall/ -- Cascal N.V. (NYSE: HOO) ("the Company"), a leading provider of water and wastewater services in seven countries, today announced that it plans to present at the 3rd Annual JPMorgan Basics & Industrials Conference at the Sheraton New York Hotel & Towers in New York City on Tuesday, June 3 at 2:15 PM Eastern Time.

Stephane Richer, Cascal's Chief Executive Officer, will provide an overview of the business and financial highlights, and will be available for one-on-one meetings following the Company's presentation. Institutional investors interested in scheduling a meeting with management are asked to contact Yemi Rose at (212) 896-1233.

To access the live Web Cast of this event, please visit http://metameetings.com/webcasts/jpmorgan/basicsandindustrials08/

About Cascal N.V.

Cascal provides water and wastewater services to its customers in seven countries: the United Kingdom, South Africa, Indonesia, China, Chile, Panama and The Philippines. Cascal's customers are predominantly homes and businesses representing a total population of approximately 3.6 million.

Investor Contacts:

KCSA Strategic Communications

Jeffrey Goldberger / Yemi Rose

+1 212.896.1249 / +1 212.896.1233

jgoldberger@kcsa.com / yrose@kcsa.com


'/>"/>
SOURCE Cascal N.V.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Stryker to Present at Investor Conferences
2. New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference
3. The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th
4. MedAssurants Dr. Keith Dunleavy to Present at AHIPs Institute 2008
5. AMN Healthcare Services to Present at the BMO Capital Markets 2008 Healthcare Staffing Forum
6. ev3 Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
7. Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress
8. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
9. Bioniche Presents Pre-Clinical Research at Two International Conferences
10. VNUS Medical Technologies to Present at FBR Capital Markets 12th Annual Spring Investor Conference
11. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ls about how proteins used to destroy bacteria and...nar K. Gouras, associate professor of neurology an... University, New York, and colleagues provide new ...alled antibodies, reduce the main hallmarks of Alz...
... scientific method for testing and measuring xanth...nducted on XanGo Juice , indicate usage of the who... high xanthone absorption. XanGo, LLC, recognized...t category is leading scientific exploration of th...
...ng all possible arrangements to look good on her y...o sources, the first thing that the socialite will... dry face. Hilton has resentfully complained to t...that she's not permitted to have facial moisturize...
...y who were destined to go blind within five years ...treatment with Avastin , a well-known cancer drug,...ne, 2007 Archives of Ophthalmology. This is a majo...ts who are treated with radiation therapy and comm...
Other Medicine News:Health News:Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment 2Health News:Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment 3Health News:New Technique to Measure Xanthone in Mangosteen 2Health News:New Technique to Measure Xanthone in Mangosteen 3Health News:Untreatable Eye Disease Improves With Avastin 2
(Date:8/26/2008)...IANAPOLIS, Aug. 26 /- Semafore Pharma...national Congress on Targeted Therapies,in Cancer ...ovel,multi-targeted kinase inhibitors that demonst...l studies., A novel and proprietary molecular sca...ing allowing for the design of pan-PI3 kinase inhi...
(Date:8/26/2008)...T WORTH, Texas, Aug. 26 /- Healthpoin... trial to evaluate the effectiveness of a,widely p...aneous wounds and,resulting scars. The pilot study... reduced incidence of hypertrophic scars and benef...se SANTYL(R) Ointment.(1,2), "Given the findings ...
(Date:8/26/2008)...LO PARK, Calif., Aug. 26 /-... the positive one-year follow-up data,from the CUS...e of the,peer-reviewed journal, EuroIntervention. ...tella, M.D., of University Medical Center Utrecht,...II Investigators from 13 clinical,sites across Eur...
(Date:8/26/2008)...TTLE, Aug. 26 /- Omeros Corporation t... a Phase 1/Phase 2 trial investigating,OMS103HP in...onstruction,surgery. OMS103HP is an investigationa...ation solution and is designed to improve postoper...ve pain and allow patients an,earlier return to wo...
Breaking Medicine Technology:Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2New technology enhances therapeutic potential of cord blood stem cells 3551 1New technology enhances therapeutic potential of cord blood stem cells 3551 2DURECT Corporation to Participate in Upcoming Healthcare Conferences 5853 1Walking Golf Course Affects Swing Performance 21249 1Walking Golf Course Affects Swing Performance 21249 2US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 1US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 2US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 3US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 4US FDA Grants Pediatric Exclusivity for UCBs Keppra 28R 29 5852 5
...he Intramuscular Formulation,of Peramivir Supports...za, BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-Fi...ed results from two Phase I,clinical studies of an...the Options for the Control of Influenza Conferenc...ional influenza,conference is held only once every...
...PRNewswire-FirstCall/ --,Genaera Corporation today...quemine (MSI-1436), its novel anti-obesity compoun...67th Scientific,Sessions, June 22 to 25 in Chicago...ine is a Multiple,Pathway Inhibitor that Causes Di...roves Plasma Insulin and Leptin Levels." , The pos...
Other Medicine Technology:BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 2BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 3BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 4BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 5BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 6Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 2Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 3Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 4
...ld, point-of-care device for the qualitative detec...The TOX/See device can detect up to nine of the mo...uires only a few drops of urine. Each TOX/See cass...nce and ease of use. TOX/See features integrated t...
...ld, point-of-care device for the qualitative detec...The TOX/See device can detect up to nine of the mo...uires only a few drops of urine. Each TOX/See cass...nce and ease of use. TOX/See features integrated t...
...ld, point-of-care device for the qualitative detec...The TOX/See device can detect up to nine of the mo...uires only a few drops of urine. Each TOX/See cass...nce and ease of use. TOX/See features integrated t...
...ld, point-of-care device for the qualitative detec...The TOX/See device can detect up to nine of the mo...uires only a few drops of urine. Each TOX/See cass...nce and ease of use. TOX/See features integrated t...
Medicine Products: